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ABSTRACT: Rod outer segment membrane guanylate cyclase1 (ROS-GC1) is the original member of the
membrane guanylate cyclase subfamily whose distinctive feature is that it transduces diverse intracellularly
generated Ca2+ signals in the sensory neurons. In the vertebrate retinal neurons, ROS-GC1 is pivotal for
the operations of phototransduction and, most likely, of the synaptic activity. The phototransduction- and
the synapse-linked domains are separate, and they are located in the intracellular region of ROS-GC1.
These domains sense Ca2+ signals via Ca2+-binding proteins. These proteins are ROS-GC activating
proteins, GCAPs. GCAPs control ROS-GC1 activity through two opposing regulatory modes. In one
mode, at nanomolar concentrations of Ca2+, the GCAPs activate the cyclase and as the Ca2+ concentrations
rise, the cyclase is progressively inhibited. This mode operates in phototransduction via two GCAPs: 1
and 2. The second mode occurs at micromolar concentrations of Ca2+ via S100â. Here, the rise of Ca2+
concentrations progressively stimulates the enzyme. This mode is linked with the retinal synaptic activity.
In both modes, the final step in Ca2+ signal transduction involves ROS-GC dimerization, which causes
the cyclase activation. The identity of the dimerization domain is not known. A heterozygous, triple mutation
-E786D, R787C, T788M- in ROS-GC1 has been connected with autosomal cone-rod dystrophy in a
British family. The present study shows the biochemical consequences of this mutation on the
phototransduction- and the synapse-linked components of the cyclase. (1) It severely damages the intrinsic
cyclase activity. (2) It significantly raises the GCAP1- and GCAP2-dependent maximal velocity of the
cyclase, but this compensation, however, is not sufficient to override the basal cyclase activity. (3) It
converts the cyclase into a form that only marginally responds to S100â. The mutant produces insufficient
amounts of the cyclic GMP needed to drive the machinery of phototransduction and of the retinal synapse
at an optimum level. The underlying cause of the breakdown of both types of machinery is that, in contrast
to the native ROS-GC1, the mutant cyclase is unable to change from its monomeric to the dimeric form,
the form required for the functional integrity of the enzyme. The study defines the CORD in molecular
terms, at a most basic level identifies a region that is critical in its dimer formation, and, thus, discloses
a single unifying mechanistic theme underlying the complex pathology of the disease.
Phototransduction is a biochemical process by which the
vertebrate rods and cones generate electrical signals in
response to captured photons (reviewed in refs 1 and 2). This
process occurs in the rod (or cone) outer segments (ROS).1
The photon induces a decline in the level of cyclic GMP
and closure of the cyclic GMP-gated cation channels. This
results in a drop of intracellular Ca2+ from 500 nM in dark-
adapted photoreceptor cell to below 100 nM after illumina-
tion. This drop activates ROS guanylate cyclase (ROS-GC).
Increased synthesis of cyclic GMP, concomitant with the
inactivation of the phototransduction cascade, leads to the
reopening of the cyclic GMP-gated channels and restoration
of the dark current of the photoreceptors. Thus, two pivotal
molecules, Ca2+ and cyclic GMP, are interlocked in a
reciprocal feedback loop.
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There are two forms of ROS-GC, termed ROS-GC1 and
ROS-GC2 (1). Both reside in photoreceptors and mimic the
native cyclase activity under conditions of phototransduction;
yet, only ROS-GC1 has been firmly linked with phototrans-
duction. To date, (1) only ROS-GC1 presence in ROS has
been demonstrated via its direct purification from ROS and
its partial sequencing (3, 4); (2) mutations that cause loss of
ROS-GC1 expression lead to defects in retinal morphology
as well as visual transduction in human (5) and chicken (6);
and (3) ROS-GC1 mutations specific to rod- or rod-cone
specific abnormalities explain the disease phenotype in
molecular terms (7-9).
ROS-GC represents a subfamily of membrane guanylate
cyclases (1, 10). It distinguishes itself from the other
subfamily of surface receptors in that it is not regulated by
extracellularly generated signals. In contrast, it is modulated
by intracellularly generated Ca2+ signals in the vertebrate
sensory neurons of the retina and the pinealocytes (1, 11). It
senses Ca2+ signals indirectly via Ca2+-binding proteins:
GCAPs and S100â. Consistent with the membrane guanylate
cyclase family trait, both ROS-GC subfamily members are
single transmembrane-spanning proteins, with an extracel-
lular segment and an intracellular segment of almost equal
length. A 26 amino acid transmembrane domain separates
the two segments (10, 12-15). A modulatory feature of
ROS-GC1, unique to itself, has started to emerge. ROS-GC1
responds to multiple Ca2+ signals, four of which have been
recognized. One signal is mediated by GCAP1, this is linked
with phototransduction (16-19); the second, also presumably
linked with phototransduction, is mediated by GCAP2 (20-
22); the third, linked with the retinal synaptic activity, is
mediated by S100â (23-25). The fourth Ca2+ signal is
mediated by neurocalcin (26). The physiological importance
of this signal is not clear, however. Each signal is transduced
by ROS-GC1 specific module. The Ca2+-sensing modules
reside in the intracellular region of ROS-GC1 where in a
signal-specific manner they individually control the core
catalytic cyclase module. Phototransduction-linked, GCAP1-
signaling ROS-GC1 module has been mapped (27). It is
composed of two domains: M445-L456, the transduction
domain, and L503-I522, the binding domain (27). The
GCAP2- and S100â-modulated ROS-GC1 domains, which
reside at the C-terminal region of the cyclase, have not been
mapped (22, 23, 28). An intriguing regulatory feature of the
phototransduction-linked and the retinal synapse-linked ROS-
GC1 modules is that they translate Ca2+ signals into the
production of cyclic GMP in opposite fashions. The photo-
transduction-linked ROS-GC1 modules, at nanomolar con-
centrations of Ca2+ and in the presence of GCAPs, mediate
activation of the cyclase and progressively inhibit it as the
Ca2+ concentrations near the micromolar range. On the other
hand, the micromolar ranges of Ca2+ progressively stimulate
the cyclase via S100â. Thus, the ROS-GC1 is precision
machinery designed to sense and appropriately respond to
Ca2+ signals, resulting in the enhanced or decreased produc-
tion of cyclic GMP.
Very recent studies have started to indicate an important
structural prerequisite of ROS-GC1, which is essential for
its functional integrity. The cyclase must be in a dimeric
form to be active (29, 30). The identity of the dimerization
domain is not known.
Almost complete (31) and partial structure (32, 33) of the
ROS-GC1 gene has been elucidated. This information has
allowed to link specific point mutations in the gene with
several types of rod- and cone-associated abnormalities (34-
40). These abnormalities in extreme cases, such as Leber’s
congenital amaurosis (LCA1), cause blindness at birth, and
in less severe cases, such as cone-rod dystrophy type 6
(CORD6), there is progressive deterioration in vision,
ultimately, also leading to blindness. Several ROS-GC1
mutations spread over both extra- and intracellular domains
of the protein have been detected in LCA1-afflicted patients
(34-36). However, to date, only in the case of F514S
mutation, the biochemical consequences have been deter-
mined and the disease phenotype has been explained in terms
of altered ROS-GC1 function (7). Since this original finding,
several similar investigations linking ROS-GC1 mutations
with LCA1 and CORD6 have begun to emerge (8, 9).
In a newly identified CORD6 case, a heterozygous
mutation of three amino acids, which are at adjacent positions
-E786D, R787C, T788M- occurs in ROS-GC1 (37). This
triple mutation results in dominant cone-rod dystrophy,
which, in turn, leads to an early loss in the clarity of vision
and color distinction. Progressive night blindness and
deterioration in the peripheral visual field follow.
The objective of the present study was to determine at a
biochemical and functional level the effect of the CORD6-
triple mutation -E786D, R787C, T788M (ERTfDCM)-
on the phototransduction and the retinal-synapse linked
modules of ROS-GC1 and, thus, to define pathology of the
disease in precise molecular terms. The findings demonstrate
that the mutation strikingly alters the Ca2+-sensing machinery
of these modules. In addition, at a most basic level, the study
identifies a region in ROS-GC1 that is critical for dimer
formation, providing a single unifying mechanistic theme
underlying the complex pathology of the disease.
MATERIALS AND METHODS
Construction of ROS-GC1 Mutant. The CORD-6 related
triple mutation, ERTfDCM, was introduced into ROS-GC1
cDNA in pcDNA3 expression vector by “Quick Change”
mutagenesis (Stratagene) according to the manufacturer’s
protocol. The mutated recombinant was sequenced to confirm
its identity. The N-terminal FLAG (DYKDDDDK) epitope
was inserted into the cDNA immediately after the signal
peptide cleavage site as described previously (3, 7, 8, 10).
Expression and Purification of GCAP1 and GCAP2. The
bovine GCAP1 cDNA was expressed in Escherichia coli
ER2566 strain and purified to homogeneity as described in
ref 7. The bovine GCAP2 cDNA was expressed in Sf9 insect
cells and purified to homogeneity as described in refs 15,
22, and 41 or in E. coli BL21(DE3)/pLysS strain as described
below. The coding sequence of bovine GCAP2 was amplified
from the clone GCAP2/pVL1393 by polymerase chain
reaction (PCR) using the following primers: 5′-AAATTC-
CATATGGGGCAGCAGTTC (sense primer introducing an
NdeI site encompassing the ATG start codon) and 5′-
GCCCCGAATTCATCAGAACATGGC (antisense primer
an additional STOP codon and an EcoRI restriction site).
The product was subcloned into the pET221a(+) vector
(Novagene) via the introduced restriction sites (15). The
resulting plasmid was sequenced to confirm its identity.
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GCAP2 protein was expressed in an E. coli BL21(DE3)/
pLysS strain carrying the plasmid pBB131 (a kind gift of
Dr. J. Gordon) encoding for yeast N-myristoyl transferase.
Cells were grown at 37 °C to an OD600 of approximately
0.5 in LB medium containing 100 íg/mL ampicillin, 12.5
íg/mL chloramphenicol, and 30 íg/mL kanamycin, then
supplemented with 50 íg/mL myristic acid. Thirty minutes
after the addition of myristic acid, the expression of GCAP2
was induced by the addition of isopropyl-1-thio-â-D-galac-
tosidase (IPTG) to a final concentration of 0.5 mM. Expres-
sion was allowed to proceed for 4 h. Induced cells from 1 L
of culture were collected by centrifugation, resuspended in
50 mL of 50 mM Tris-HCl, pH 8, and stored frozen at -20
°C until further use. The thawed cell suspension was
incubated at 30 °C for 30 min in the presence of 100 íg/mL
lysozyme (SERVA) and 10 units/mL DNase1 (TaKaRa).
Lysis was terminated by the addition of 1 mM DTT (1,4-
ditiothreitol) and 0.1 mM PMSF (phenylmethanesulfonyl
fluoride). The insoluble fraction was collected by centrifuga-
tion at 370000g for 20 min and solubilized by stirring in
250 mL of a buffer containing 6 M guanidinium hydrochlo-
ride, 0.1 mM PMSF, and 2.5 mM DTT for 1 h at room
temperature. The resulting suspension was filtered and
dialyzed at 4 °C against three changes of 10 mM sodium
phosphate buffer, pH 7, containing 1 mM EDTA and 1 mM
DTT, followed by two changes of 10 mM sodium phosphate
buffer containing 200 íM CaCl2 and 1 mM DTT. Precipi-
tated material was removed by centrifugation at 370000g
for 20 min. The supernatant was concentrated using Centri-
plus devices (Amicon) with a molecular cutoff of 10 kDa.
The concentrate was then applied to a Superdex75 XK16/
60 gel-filtration column (Pharmacia) in 10 mM sodium
phosphate buffer, pH 7, 100 mM NaCl, 200 íM CaCl2.
Fractions containing recombinant GCAP2 were pooled and
bound to an UnoQ 6 column. Elution was performed by a
gradient of 50-500 mM NaCl in 5 mM sodium phosphate
buffer, pH 7, containing 20 íM CaCl2. Recombinant GCAP2
was obtained in >95% purity, as determined by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) followed by Coomassie staining.
Expression Studies. (i) COS Cells. COS-7 cells (simian
virus 40-transformed African green monkey kidney cells),
maintained in Dulbecco’s modified Eagle’s medium with
penicillin/streptomycin and 10% fetal bovine serum, were
transfected with the expression constructs FLAG-ROS-GC1
or FLAG-ERTfDCM by the calcium phosphate coprecipi-
tation technique (42). Sixty hours after transfection, cells
were washed twice with 50 mM Tris-HCl (pH 7.5)/10 mM
MgCl2 buffer, scraped into 2 mL of ice-cold buffer,
homogenized, centrifuged for 15 min at 5000g, and washed
several times with the same buffer; the pellet represented
the crude membranes. (ii) HEK293 Cells. HEK293 cells
(human embryonic kidney cells) were grown in minimal
essential medium (Eagle) with 2 mM glutamine, 10% fetal
calf serum, 1% nonessential amino acids, and 1% antimy-
cotic/antibiotic solution. They were transfected with the
appropriate expression constructs and the plasmid pRSV-
TAG (43) by the calcium phosphate method (42). To enhance
the expression of ROS-GC1 and its mutant, sodium butyrate
(0.5 M in PBS) was added to a final concentration of 0.75
mM at 30 h posttransfection. 48 h posttransfection, the cells
were harvested, washed with PBS, resuspended in 100 íL
of lysis buffer (10 mM HEPES-KOH pH 7.5, 1 mM DTT,
0.1 mM PMSF), sonicated and centrifuged to remove cellular
debris. The resulting supernatant was centrifuged at 4500
rpm for 15 min. The pelleted membranes were resuspended
in 50 íL of lysis buffer (10 mM HEPES-KOH pH 7.5, 250
mM KCl, 10 mM NaCl, 1 mM DTT). Protein concentrations
of the membrane suspensions were determined with the
amido black method using bovine serum albumin as a
standard (44).
Guanylate Cyclase ActiVity Assay. The crude membranes
of COS cells were assayed for guanylate cyclase activity as
described previously (7, 8). Briefly, the membranes were
preincubated in an ice-bath with or without GCAP1, GCAP2,
or S100â in the assay system containing 10 mM theophylline,
15 mM phosphocreatine, 20 íg of creatine kinase, and 50
mM Tris-HCl (pH 7.5) and adjusted to the appropriate free
Ca2+ concentrations with precalibrated Ca2+/EGTA solutions
(Molecular Probes). Total assay volume was 25 íL. The
reaction was initiated by the addition of the substrate solution
containing 4 mM MgCl2 and 1 mM GTP (final concentra-
tion). Incubation (37 °C, 10 min) was terminated by the
addition of 225 íL of 50 mM sodium acetate buffer (pH
6.25) followed by heating in a boiling water bath for 3 min.
The amount of cyclic GMP formed was determined by
radioimmunoassay (45).
HEK293 cell membranes were assayed for their guanylate
cyclase activity in the presence of 100 íM ATP and 400
íM Zaprinast as described previously (27). Basal activities
were determined with manganese as cofactor.
Western Blot. After boiling in gel-loading buffer [62.5 mM
Tris-HCl (pH 7.5), 2% SDS, 5% glycerol, 1 mM â-mercapto-
ethanol, and 0.005% bromophenol blue], 20 íg of membrane
protein was subjected to SDS-PAGE in a buffer (pH 8.3)
containing 0.025 M Tris, 0.192 M glycine, and 0.1% SDS.
The proteins were transferred to Immobilon membranes
(Millipore) in the same buffer but containing 5% methanol.
The blot was incubated in Tris-buffered saline (TBS, pH 7.5)
containing 100 mM Tris-HCl, 0.9% NaCl, and 0.05% Tween-
20 (TBS-T) with 5% powdered nonfat Carnation milk
(blocking buffer) overnight at 4 °C and rinsed with TBS-T.
The anti-FLAG monoclonal antibodies (Sigma) were added
at 1:300 dilution in the blocking buffer and the incubation
was continued for 1 h. After the blot was rinsed with TBS-
T, the incubation was continued with the secondary antibody
conjugated to horseradish peroxidase in blocking buffer (1:
20000) for another hour. Finally the blot was treated with
SuperSignal blaze chemiluminescent substrate (Pierce) for
5 min according to the manufacturer’s protocol. The immu-
noreactive band was detected by exposing the blot to Kodak
X-ray film for 15 s.
Cross-Linking. Cross-linking was performed using homo-
bifunctional N-hydroxy-succinimide (NHS) ester harboring
a spacer with length of 11.4 Å, the water-soluble bis-
(sulfosuccinimidyl)suberate (BS3, Pierce). The cross-linker
was added to a ROS suspension (1 mg of rhodopsin) at a
final concentration of 1 mM. The reaction mixture (0.1 mL)
was incubated for 20 min at room temperature and the
reaction was stopped by the addition of 50 mM Tris-HCl,
pH 8.0. For cross-linking of the heterologously expressed
ROS-GC1 and its mutant, HEK293 membranes were diluted
by half with a solution containing 2 mM BS3. The reaction
mix was incubated for 15 min at room temperature. The
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influence of Ca2+-binding proteins on the cross-linking
efficiency was assayed at a final concentration of 10 íM of
GCAP-1, GCAP-2, or S100â, respectively. Samples with
Ca2+-binding proteins were incubated in the presence of 2
mM EGTA or 2 mM CaCl2. The cross-linking reaction was
stopped by the addition of three volumes of SDS-PAGE
sample buffer. Samples were analyzed for cross-linked
products by SDS-PAGE and Western blotting using a
polyclonal anti ROS-GC1 antibody (1:5000) and HRP-
coupled secondary antibody (anti rabbit IgG) (46). Bands
were detected by enhanced chemiluminescence (ECL). For
quantitation of bands, the chemiluminescence was recorded
with an Image Station 440 CF (Kodak). The resulting images
were digitally stored and evaluated using Kodak Digital
Science 1-D software (version 3.02).
Gel-Filtration Chromatography. (1) Expression and Pu-
rification of the aa 733-1054 Fragment of wt-rROS-GC1
and of the ERTfDCM Mutant. A 966 bp fragment corre-
sponding to aa 733-1054 of wt-rROS-GC1 (10) and of the
ERTfDCM mutant was amplified by PCR and cloned in
frame into pET30a bacterial expression vector (Novagen)
between EcoRV and XhoI sites. The construct was verified
by sequencing and transformed into E. coli ER2566 for
expression. Initially, clones were screened for inducible
expression of the ROS-GC1 fragment. For a large scale
culture, overnight grown cells (1%) were inoculated into LB
containing 100 íg/mL kanamycin and grown to an OD of
0.6 at 600 nm. At this stage, expression of the fragment was
induced by the addition of IPTG (1 mM final concentration).
The cells were harvested 3-4 h after induction and resus-
pended in 0.04 vol of buffer containing 20 mM Tris-Cl and
300 mM NaCl. This suspension was sonicated (8 pulses of
20 s each) to break open the cells. This was followed by
centrifugation at 13000g to pellet the inclusion bodies, which
contained the expressed protein. The inclusion bodies were
resuspended in buffer containing 100 mM sodium phosphate,
10 mM Tris-Cl, 2 mM DTT, and 8 M urea (pH 8.0) and
incubated for 60 min at room temperature with shaking to
extract the proteins into the buffer. After 60 min, the debris
was pelletted by centrifugation. The supernatant was incu-
bated with 0.25 volumes of Ni-NTA resin (Qiagen) (pre-
equilibrated in the same buffer) at room temperature on a
rotary shaker for 2-5 h. This suspension was loaded on a
column, where the His-tagged protein was retained with the
Ni-NTA resin. The column was washed with 20 vol of buffer
containing 100 mM sodium phosphate, 10 mM Tris-Cl, and
8 M urea (pH 6.3) followed by 4 vol of the same buffer at
pH 5.9. The expressed protein was eluted with 4 vol of the
same buffer at pH 4.5. Refolding of the eluted protein was
carried out according to ref 48. After dialysis, the protein
solution was concentrated using centricon-30 filters (Milli-
pore). The protein thus obtained was of >95% purity as
determined by SDS-PAGE. (2) Gel-Filtration. This was
carried out on a Superdex-75 column using an LCC-501
controller managed by fast-protein liquid chromatography
(FPLC) director on an FPLC system (Pharmacia Biotech).
The sample was loaded using a 100 íL loop and eluted with
a buffer containing 20 mM Tris-Cl and 150 mM NaCl (pH
7.4). The flow rate was maintained at 0.5 mL/min. and 0.5
mL fractions were collected. The elution was monitored by
measuring absorbance at 280 nm. The major peak was that
of guanylate cyclase. This peak fraction was independently
identified based on enzyme activity. Quantitation of the peak
was carried out through integration of the area under the
peak after subtraction of the baseline.
RESULTS
ERTfDCM Mutation in ROS-GC1 Damages the Basal
Cyclase State. CORD6 is heterogeneous. Previous studies
have linked two missense point mutations in the ROS-GC1
gene, resulting in the amino acid substitutions E786D and
R787C, with this disease in four British families (38). Each
inflicted family contains only one of the above mutations.
Biochemically, these mutations produce varying effects on
the basal cyclase activity, and they have been discussed in
detail in previous studies (8, 9). The triple mutation linked
with another case of CORD6 involves amino acids: E786,
R787, and T788 (37). This indicates that all CORD6 cases
reported so far cover amino acids at adjacent positions in
ROS-GC1, hence, this region of the cyclase is mutation-
prone. Alignment of a 13 amino acid domain surrounding
the E786, R787, and T788 residues shows complete identity
between its human, dog, rat, mouse, and bovine forms
(Figure 1). Thus, the region is totally conserved in ROS-
GC1.
To elucidate how the ERTfDCM substitutions affect the
biochemical features of ROS-GC1, these mutations were
FIGURE 1: Schematic representation of the ROS-GC1 protein. The following denote the predicted domains: LS, leader sequence; EXT,
extracellular (intradiscal) domain; TM, transmembrane domain; DD, dimerization domain. Numbers indicated correspond to the mature
protein (11). Alignment of the human, dog, rat, mouse, and bovine amino acid sequences (GenBank accession numbers M92432/AJ222675,
Y15483, Y15483, L36029, L41933, L37089, respectively) in the region surrounding positions 786, 787, and 788 is shown.
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introduced into wild-type recombinant (wt-r) ROS-GC1. The
cyclase was expressed in COS cells which under native
conditions do not express ROS-GC1. ROS-GC1 leader
sequence was retained in the expression construct to ensure
proper translocation and folding of the protein. The cell
membranes expressing the wt-rROS-GC1 or the mutant were
tested for basal cyclase activity. In parallel, the expression
level of the protein was assessed. A highly immunogenic
FLAG (DYKDDDDK) epitope was inserted into the cyclases
immediately after the signal peptide cleavage site (3, 10).
Insertion of FLAG sequence does not alter the basal cyclase
activity (7, 8). COS cell membranes expressing the FLAG-
containing constructs were subjected to Western analysis with
anti-FLAG monoclonal antibodies. The blots showed single
immunoreactive bands of almost equal intensity (Figure 2B),
indicating comparable expression of the proteins.
The basal activity of the wt-rROS-GC1 was 130 ( 10
pmol of cyclic GMP min-1 (mg of protein)-1. In contrast
the activity of the ERTfDCM mutant was 30 ( 5 pmol of
cyclic GMP min-1 (mg of protein)-1 (Figure 2A). This
indicates that the mutation severely damages the basal state
of the enzyme.
ERTfDCM Mutation Increases the ActiVity of Photo-
transduction-Linked Modules of ROS-GC1. There are pre-
sumably two phototransduction-linked modules in ROS-GC1.
GCAP1 modulates one and GCAP2, the other. These are
distinct modules, which do not overlap with each other (8,
22). The current phototransduction model predicts that
GCAPs are bound to the cyclase in its native state (16, 27).
They are under tight control of the intracellular levels of
Ca2+. Increments in Ca2+ are sensed by the GCAPs and cause
progressive decrease in the activity of ROS-GC1. To
determine whether the ERTfDCM mutation has any effect
on the cyclase response to these modulators, COS cell
membranes expressing the wt-rROS-GC1 or the mutant
protein were exposed to increasing concentrations of GCAP1
or GCAP2 at a Ca2+ concentration of 10 nM. GCAP1
stimulated both cyclases in a dose-dependent fashion with
EC50 of 1 íM and saturation at 3 íM. There was a
significant difference in the maximal activation achieved by
the cyclases. The wt-rROS-GC1 was stimulated approxi-
mately 10-fold over the basal value, but the ERTfDCM
mutant, almost 18-fold (Figure 3A). However, this increased
responsiveness of the ERTfDCM mutant to GCAP1 was
not enough to compensate for the loss in the mutant’s basal
activity. The amount of cyclic GMP formed at any GCAP1
FIGURE 2: Expression of the wt-rROS-GC1 and of the triple
substitution ERTfDCM mutant proteins. (A) Guanylate cyclase
actiVity. COS7 cells were individually transfected with the ap-
propriate expression constructs, and the membranes were prepared
as described under Materials and Methods. These were assayed
for guanylate cyclase activity. The experiment was repeated three
times for reproducibility. (B) Western blot. Proteins (20 íg of COS7
cell membranes containing FLAG-ROS-GC1 of FLAG-ERTfDCM)
were subjected to SDS-PAGE. After electrophoresis the proteins
were transferred to Immobilon membranes, and the blots were
incubated with anti-FLAG monoclonal antibody and with the
secondary antibody as described under Materials and Methods.
Immunoreactive bands were visualized by exposing the blots to
Kodak X-ray film. The experiment was repeated three times with
membranes prepared from separate transfection experiments.
FIGURE 3: Effect of GCAP1 on the cyclase activity of the wt-
rROS-GC1 and ERTfDCM mutant proteins. COS7 cells were
transfected with appropriate expression constructs and the mem-
branes were prepared as described under Materials and Methods.
These were assayed for guanylate cyclase activity in the presence
of 10 nM Ca2+ and incremental concentrations of GCAP1. The
guanylate cyclase activity was calculated as fold stimulation above
the basal value (A) or as the cyclase specific activity (B). Each
experiment was done in triplicate and repeated at least three times
with separate membrane preparations. The depicted curves are from
one representative experiment. Error bars are within the size of
the symbols.
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concentration was no more than 35% of the amount formed
under the same conditions by wt-rROS-GC1 (Figure 3B).
Thus, the mutation leads to a state where the cyclase becomes
overresponsive to GCAP1 stimulation, but the net formation
of cyclic GMP is impaired due to lowered basal activity.
When the effect of GCAP2 was tested, the ERTfDCM
mutant responded again with an increased stimulation in
comparison with wt cyclase. The maximal stimulation was
12.5-fold over the basal value for the mutant, whereas the
wt-rROS-GC1 was stimulated 7.5-fold (Figure 4A). There
was small, albeit noticeable, difference in the respective EC50
values for GCAP2: the EC50 value in case of the mutant
was 4 íM while it was 8 íM in case of the wt-rROS-GC1
(Figure 4A). Thus, the mutation results in a small increase
in the cyclase affinity for GCAP2. However, despite the
increased responsiveness and affinity toward GCAP2, the
ERTfDCM mutant is able to synthesize only about one-
third of the cyclic GMP compared to the wt cyclase (Figure
4B).
To determine whether the ERTfDCM mutation alters the
Ca2+ sensitivity of GCAP1- or GCAP2-dependent stimulation
of the cyclase, the Ca2+-dependent modulation of the cyclase
was tested at varying concentrations of Ca2+ and constant
concentrations of GCAP1 or GCAP2 (Figure 5, panels A
and B). The pattern was identical for the wt and mutant ROS-
GC1. The cyclase activity decreased when the free Ca2+
increased. Half-maximal inhibition (IC50) was at about 110
nM free Ca2+. Thus, the ERTfDCM mutation does not
affect the calcium sensitivity of the cyclase. It, however,
diminishes the responsiveness of the cyclase to GCAPs. In
the final analysis, the mutation has altered the phototrans-
duction-linked modules of the cyclase without altering their
calcium sensitivity.
ERTfDCM Mutation Drastically Reduces the ActiVity of
the Synapse-Linked Module of ROS-GC1. In addition to being
linked with phototransduction, ROS-GC1 is also linked with
the retinal synapse activity. The linkage occurs via a module,
which is distinct from those linked with phototransduction
(23, 28). Here Ca2+ through S100â stimulates the module.
To determine whether the ERTfDCM substitution has any
effect on the synapse-linked module, the membranes ex-
pressing the mutant were assayed for the cyclase activity in
the presence of increasing concentrations of S100â, at 1 mM
Ca2+. Control experiments were carried out with wt-rROS-
GC1. Although the mutant was stimulated in a dose-
dependent fashion, the maximal stimulation achieved was
three times lower than that of wt-rROS-GC1: 5-fold
stimulation was observed for the mutant whereas wt-rROS-
GC1 was stimulated 15-fold (Figure 6A). When the
amounts of cyclic GMP formed by the mutated and wt-
cyclases were compared, the difference was even more
striking. At the maximal concentration of S100â, the amount
of cyclic GMP formed by the mutated cyclase was only
5-8% of the amount formed by wt-rROS-GC1 (Figure 6B),
although no change in sensitivity to Ca2+ was observed
(Figure 5C). This indicates that this module is almost
completely nonfunctional in the mutant. Thus, the mutation
has incapacitated the retinal synapse-linked module.
HEK293 and COS Cells Expression Systems Are Com-
parable. It was noticed that the use of COS or HEK293 cells
for the expression of ROS-GC1 or its mutants occasionally
leads to different results (27). Therefore, the consequences
of the ERTfDCM substitution in ROS-GC1 were tested
using the HEK293 system in addition to the COS cell
expression system. Qualitatively, the results obtained with
both systems were similar. The basal activity decreased to
about 15 ( 9% of the value measured with the wt-rROS-
GC1. The mutant was also over-responsive to GCAP1 but
less responsive to GCAP2 and lost nearly all responsiveness
to S100â up to a concentration of 5íM (Figure 7). At
maximal S100â concentration (10 íM), the ERTfDCM
mutant retained only 7% of the activity measured with the
wt-rROS-GC1. Some difference was observed in the dose-
response patterns. Higher concentrations were needed to
reach half-maximal activation of the wt and the ERTfDCM
mutant with GCAP1 and S100â, but not GCAP2. Thus, it is
FIGURE 4: Effect of GCAP2 on the cyclase activity of the wt-
rROS-GC1 and ERTfDCM mutant proteins. The experimental
conditions were as described for GCAP1, except that GCAP2 was
used. The guanylate cyclase activity was calculated as fold
stimulation above the basal value (A) or as the cyclase specific
activity (B). Each experiment was done in triplicate and repeated
at least three times with separate membrane preparations. The
depicted curves are from one representative experiment. Error bars
are within the size of the symbols.
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concluded that the effect of the ERTf DCM mutation is
similar in both the systems tested, although some important
quantitative variations are observed. Significantly, in HEK293
cells, GCAP1 and GCAP2 are almost equipotent in stimulat-
ing ROS-GC1.
ERTfDCM Substitution Affects ROS-GC1 Dimerization.
Analyses of the results presented above indicate that under
all tested experimental conditions, the amount of cyclic GMP
formed by the ERTfDCM mutant is lower than that formed
by wt-rROS-GC1. Earlier studies have indicated that the
active state of ROS-GC1 is represented by its dimeric form
(29, 30). To determine if the impaired functioning of the
cyclase is a result of disturbed dimer formation, the dimer-
ization of the wt and mutated ROS-GC1 was tested by cross-
linking and gel-filtration chromatography.
(i) Cross-Linking. When native ROS-GC1 in a suspension
of bovine ROS was incubated with the cross-linker BS3, two
main bands, in addition to the ROS-GC1 monomer at 112
kDa, were detected by the anti-ROS-GC1 antibody (Figure
8A, left panel). The band at 220 kDa represented a ROS-
GC1 dimer; the band at the top gel was an oligomeric form
of ROS-GC1 with an apparent molecular mass of more than
400 kDa.
A similar cross-linking pattern was observed when wt-
rROS-GC1 was heterologously expressed in HEK293 cells
and subsequently cross-linked with BS3 (Figure 8A, middle
panel). This indicated that native and heterologously ex-
pressed ROS-GC1 could be directly compared with respect
to its monomeric, dimeric, and oligomeric forms. A signifi-
cant change in the formation of a dimer was observed with
the ERTfDCM mutant. The proportion of the different
forms was quantitatively analyzed based on the band
intensities. The results indicate that the ability of the
ERTfDCM mutant to form a dimer decreased by 60-70%
in comparison with the wt-rROS-GC1 (Figure 8A, right
panel). The decrease was accompanied by a corresponding
decrease in the cyclase activity (Figure 8C). Cross-linking
was not influenced by the addition of Ca2+-binding proteins,
GCAP1, GCAP2 and S100â, at 2 mM EGTA or 1 mM CaCl2
(data not shown). Thus, the ERTfDCM mutation disturbs
the dimerization of ROS-GC1 and thereby causes impairment
in the synthesis of cyclic GMP.
(ii) Gel-Filtration Chromatography. The fragments cor-
responding to aa 733-1054 of ROS-GC1 and of the
ERTfDCM mutant were expressed in bacterial cells and
purified to homogeneity. The expressed fragment encom-
passed the putative dimerization and catalytic domains of
the cyclase. Can the expressed proteins serve as a proper
model for studies on the dimerization of ROS-GC1? To test
the integrity of both fragments, their cyclase catalytic
activities and their abilities to respond to GCAP1, GCAP2,
or S100â at the appropriate free Ca2+ concentrations were
tested.
Both proteins exhibited cyclase activities (Figure 9). They
were 6 ( 0.5 and 1.5 ( 0.25 pmol of cyclic GMP min-1
(mg of protein)-1, respectively, for the ROS-GC1 and for
the mutant fragments. These activities were considerably
lower than the activities of the full length proteins. Similar
lowering of the basal activity has been observed earlier for
the expressed soluble fragments of the human analogue of
ROS-GC1 (47) and for the atrial natriuretic factor receptor
guanylate cyclase (ANF-RGC) (48, 49). Significantly,
however, the activity of the mutant-derived fragment was
4-fold lower than that of the wt-rROS-GC1-derived frag-
ment indicating that the mutations affected the soluble
fragment in a fashion similar to the full-length protein.
When exposed to 5 íM GCAP1 or 20 íM GCAP2 at 10
nM Ca2+, both fragments responded to GCAP2 with 3-
fold increased cyclic GMP formation. They, however, failed
to respond to GCAP1 (Figure 9). These results are consistent
with the previous conclusions that GCAP1- and GCAP2-
responsive ROS-GC1 modules are distinct and their domains
do not overlap (22). The lack of response with GCAP1 is
also consistent with a recent study (27), which shows that
GCAP1 sensitive module in ROS-GC1 is located in the
juxtamembrane domain. This module is missing in the
soluble fragment. However, soluble fragments derived from
both the ERTfDCM and the wt-cyclase, were stimulated
by S100â at 1 mM Ca2+ (Figure 9). These results demon-
strate that the soluble fragments retain the native biochemical
FIGURE 5: Ca2+ dependence of wt-rROS-GC1 and ERTfDCM mutant guanylate cyclase activities in the presence of 4 íM GCAP1 (A),
15 íM GCAP2 (B), or 4 íM S100â (C). Membranes of COS7 cells expressing wt-rROS-GC1 or the ERTfDCM mutant were assayed for
guanylate cyclase activity in the presence of saturating concentrations of GCAP1, GCAP2, or S100â and increasing concentrations of free
Ca2+. Each experiment was done in triplicate and repeated two times. The results presented are from one representative experiment. Error
bars are within the sizes of the symbols.
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features of ROS-GC1, are sensitive to the mutations in
question, and are therefore suitable tools for the dimerization
studies.
The monomer/dimer statuses of the wt and of the mutant
soluble fragments were determined through the gel-filtration
chromatography. The proteins were individually analyzed on
a Superdex-75 column precalibrated for molecular size in
an FPLC system. Their elutions were monitored by measur-
ing absorbancies at 280 nm and the guanylate cyclase activity
was determined in all eluted fractions. The fragment origi-
nating from wt-rROS-GC1 was eluted in two fractions. The
first fraction accounted for 75% of the protein and its
molecular weight corresponded to that of a dimer; the
remaining 25% were eluted as a monomer (Figure 10). The
fragment derived from the ERTfDCM mutant eluted as a
single peak at a position corresponding to a monomer (Figure
10). These results are consistent with the cross-linking
experiments carried out on the intact ROS-GC1. They show
that the ERTfDCM mutation within the predicted dimer-
ization domain effectively disturbs the dimer formation.
There is, however, a noticeable difference between results
of cross-linking and gel-filtration experiments, which may
be a result of different types of proteins used for analysis.
In the cross-linking studies, the full-length protein was used,
and in the gel-filtration experiments a soluble fragment of
ROS-GC1 was used. The intact protein shows some residual
ability of the mutant to dimerize, whereas the isolated soluble
fragment exhibits a complete disruption of dimerization in
the mutant. This may be due to (1) stabilization of a weak
ability to dimerize by the presence of a cross-linker; and/or
(2) interactions favoring dimerization occurring in the cyclase
regions outside the expressed portion. Despite these quantita-
tive differences, the findings in both systems indicate an
important role of dimerization in the active state of the
cyclase. They further show that the ERTfDCM mutation
interferes with the dimeric state of the cyclase.
DISCUSSION
This study defines a form of CORD6 resulting from the
ERTfDCM mutation, in biochemical, molecular, and func-
tional terms. At a most basic level, it supports the previously
proposed concept that dimerization is an important mecha-
nistic step in the activation of ROS-GC1. Furthermore, this
study identifies the residues E786, R787 and T788 to be
critical for dimerization of ROS-GC1; the ERTfDCM
mutation impairs the process of dimerization. Thus, in
ERTfDCM the enzyme is unable to fold properly and
exhibit its optimum catalytic activity. The effects of this
mutation on the basal and modulated states of ROS-GC1
are individually analyzed and their significance is discussed
under “Biochemistry” and “Physiology”. The implications
of these findings in deriving a mechanistic theme are
discussed separately. The final statements on the findings
are put together in the “Conclusion”.
Basal State. (i) Biochemistry. In its basal state, ROS-GC1
controls the dark current in the outer segments of rods and
cones. In this state 5% of the cyclic GMP-gated channels
are open (1, 50). The ERTfDCM mutation reduces the
ROS-GC1 activity by about 5-fold. This will result in the
closure of almost all of the channels.
(ii) Physiology. The closure of the channels will result in
a lowered steady-state level of cyclic GMP in dark-adapted
photoreceptor cell. Concomitant with the reduction of dark
current, there will be a drop in cytoplasmic Ca2+ concentra-
tion because of the continued operation of the exchanger (51).
This will result in a false light-adapted state of photorecep-
tors; The photoreceptor will perceive illumination without
being in a state of illumination. Another consequence of the
drop in Ca2+ levels will be that it initiates the Ca2+-dependent
feedback signals by the Ca2+ sensors, GCAP1 and GCAP2.
Thus, a shift in the response-light curve to the lower light
intensities will occur. The photoreceptors of the afflicted
individual will adapt at lower light intensities for a given
FIGURE 6: Effect of S100â on the cyclase activity of the wt-rROS-
GC1 and ERTfDCM mutant proteins. COS7 cells were transfected
with appropriate expression constructs and the membranes were
prepared as described under Materials and Methods. These were
assayed for guanylate cyclase activity in the presence of 1 mM
Ca2+ and incremental concentrations of S100â. The guanylate
cyclase activity was calculated as fold stimulation above the basal
value (A) or as the cyclase specific activity (B). Each experiment
was done in triplicate and repeated at least three times with separate
membrane preparations. The depicted curves are from one repre-
sentative experiment. Error bars are within the size of the symbols.
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background light. This prediction is borne out in the actual
case of CORD6 (38).
Phototransduction-Linked Modules. (i) Biochemistry. The
primary phototransduction-linked module in ROS-GC1 is
regulated by GCAP1 (22, 27). The ERTfDCM mutation
alters the activity of this module. As a consequence, the
maximal stimulation of the cyclase is 2-fold more than the
wt-rROS-GC1. However, due to the 5-fold lower basal
activity, the net cyclic GMP synthesized by the mutant is
only about 35% when compared to the wild-type.
A similar situation exists with the GCAP2-regulated
module in the ERTfDCM mutant. In the wt-rROS-GC1,
this is a secondary phototransduction-linked module. This
module is about 1 order of magnitude less selective in
stimulating the cyclase (22). The ERTfDCM mutation
increases the module activity: stimulation of the cyclase
through this module increases about 50% over the wt-rROS-
GC1. Again due to the lowered basal activity, the mutant,
when compared to the wild-type, produces only about one-
third of the cyclic GMP.
(ii) Physiology. The lowered levels of cyclic GMP
production by the mutant will have drastic consequences on
phototransduction. At increasing intensities of ambient
illumination, there will be a shift in the response-intensity
curve to lower light intensities. Particularly, at bright light
intensities, the insufficient cyclic GMP synthesis would drive
the photoreceptor into a state of permanent photoexcitation
and hyperpolarization. In keeping with this explanation, the
affected individuals with the mutation suffer from a decrease
in visual acuity, severe dyschromatopsia and photophobia
during their first decade of life (38). The cone dysfunction
becomes more progressive over the following decades.
Finally, the rod function is also affected resulting in loss of
peripheral vision and progressive night blindness (38).
Photophobia would result from the above-mentioned shift
in the response-intensity curve. The progressive loss of cone
function is probably the result of a permanent change in
Ca2+-homeostasis due to the low cyclic GMP content and
closure of the CNG channels.
Synapse-Linked Module. (i) Biochemistry. The retinal
synaptic activity linked module in ROS-GC1 is regulated
by S100â in a Ca2+-dependent manner (23-25). In contrast
to the phototransduction-linked modules, the activity of the
S100â-regulated module is reduced in ERTfDCM. The
reduction is over 3-fold. Taking into account the reduced
basal activity of the mutant, the enzyme in its saturated state
produces cyclic GMP, which is only 5-8% of that produced
by the wt-rROS-GC1. This indicates that the enzyme has
virtually no synapse-related activity.
(ii) Physiology. That the ERTfDCM mutation, indeed,
disrupts the retinal synaptic transmission is consistent with
the clinical observations that certain CORD6-afflicted pa-
tients show negative electroretinograms (39).
Mechanistic Implications. At a basic level, this study
reveals the critical role of aa E786, R787, and T788 in
multiple facets of ROS-GC1 modulation. The basal activity
of ROS-GC1, its regulation through the phototransduction-
and its synapse-linked modules are all altered with the
ERTfDCM mutation. Yet, the region covering these
residues is not involved in the direct binding of GCAPs or
S100 â (8). What is the role of this region in ROS-GC1
modulation? This study, for the first time, clearly establishes
that these residues are critical in the dimerization of ROS-
GC1, and that this process mediates the activity of ROS-
FIGURE 7: Effect of GCAP1 (A, D), GCAP2 (B, E), and S100â (C, F) on the cyclase activity of wt-rROS-GC1 and ERTfDCM mutant
proteins expressed in HEK293 cells. Transient expression of wt-rROS-GC1 and of the ERTfDCM mutant in HEK293 cells and the membranes
preparation were performed as described in Materials and Methods. The effect of GCAP1 and GCAP2 was analyzed in the presence of 2
mM EGTA and the effect of S100â, in the presence of 2 mM CaCl2. The experiment was done in duplicate and repeated with separate
membrane preparation. Results (mean ( SD) are expressed as specific cyclase activities (A, B, C) and fold stimulation over the activity
without the activator proteins (D, E, F).
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GC1 modules linked with phototransduction and synaptic
activity.
Recent studies show that the catalysis of the cyclic GMP
formation by ROS-GC1 occurs at a dimer interface (52) and
that its activation by GCAPs or S100â involves dimerization
step (29, 30). Thus, ROS-GC1 requires dimerization for
effective catalytic activity (29, 30). A putative dimerization
domain was proposed based purely on sequence features (9).
The present study shows that the aa E786, R787, and T788
are critical for the dimerization of ROS-GC1. The findings
demonstrate that the ERTfDCM mutation lowers the basal
cyclase activity of the mutant and also disturbs its dimer-
ization. This disruption is associated with lowered basal
activity of ROS-GC1. Although the resultant mutant is
hyperresponsive to GCAP1, the net cyclic GMP synthesized
by this mutant is only one-third of that by the wild-type.
These results show that the ERT domain is important for
dimerization, its disruption interferes with the dimerization
process, and the presence of GCAP1 can partially optimize
the dimer interface, but cannot fully compensate for the
disruption. These conclusions are reinforced by the previ-
ously published study on the R787C mutant (8). A similar
lowering of the basal activity is observed as a result of this
mutation. The mutant is hyperresponsive to GCAP1 and the
net cyclic GMP production in the presence of GCAP1, is
comparable to that of the wild-type. Thus, the defect in
dimerization of ROS-GC1 due to the R787C mutation can
FIGURE 8: Cross-linking of native ROS-GC1, wt-rROS-GC1, and
the ERTfDCM mutant. (A) Membranes of ROS or HEK293 cells
expressing wt-rROS-GC1 or the ERTfDCM mutant were incu-
bated in the absence (-) or presence (+) of 10 mM BS3; the
reaction mixtures were analyzed by SDS-PAGE (left blot 7.5%,
right blot 5%) and Western blotting. ROS-GC1 was detected with
a polyclonal anti-ROS-GC1 antibody as described in Materials and
Methods. (B) Relative intensities of monomer and dimer bands of
the wt-rROS-GC1 and the E786D, R787C, and T788M mutant
(100% corresponds to the overall signal intensity within individual
bands). (C) Guanylate cyclase activity of wtROS-GC1 and the
ERTfDCM mutant in HEK293 cell membranes preparations used
in cross-linking experiments presented in panels A and B. The
cyclase activity was assayed with Mn2+ as a cofactor. The results
depicted in panels A-C are representative for three experiments
carried out with separate membrane preparations.
FIGURE 9: Guanylate cyclase activity of the fragment corresponding
to amino acid residues 733-1054 of wt-rROS-GC1 and of the
ERTfDCM mutant. The fragments were expressed in bacterial
cells and purified as described in Materials and Methods. The
purified protein was assayed for guanylate cyclase activity with or
without GCAP1, GCAP2, or S100â at appropriate Ca2+ concentra-
tions. The experiment was repeated two times. The presented results
are from one experiment done in triplicate.
FIGURE 10: Gel-filtration chromatography. The fragments corre-
sponding to amino acid residues 733-1054 of wt-rROS-GC1 and
of the ERTfDCM mutant were expressed in bacterial cells and
purified as described in Materials and Methods. These were
analyzed by FPLC using Superdex-75 column. The elution was
monitored by measuring absorbance at 280 nm (A). Quantitation
of the peak was done through integration of the area under the
peak after subtraction of the baseline (B).
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be fully compensated by the presence of GCAP1, which
promotes optimal dimer interface. No such compensation can
occur if the two flanking residues, E786 and T788, are also
mutated.
With respect to GCAP2 and S100â, the maximal cyclic
GMP synthesized by the R787C and the ERTfDCM mutant
is significantly lower than that by the wild-type. This
indicates that the transduction steps involved in GCAP2 and
S100â signaling are distinct from those involved in GCAP1
signaling. One possible explanation is that these modulators
bind to different sites on ROS-GC1 (22, 23, 27) and cannot
compensate for the altered dimerizing ability of the mutants.
CONCLUSIONS
CORD6 is a heterogeneous disease of the cones and rods
that is caused by the mutations in ROS-GC1 gene. The
disease phenotype of the ERTfDCM mutation, the subject
of this study, is impaired vision. Knowledge of the biochem-
istry and functioning of the phototransduction- and synapse-
linked modules has allowed an incisive analysis of the effect
of this mutation on ROS-GC1 modulation. Important insights
into the biochemical and physiological aspects of ROS-GC1
function have been gained and a unifying mechanistic theme
has been identified, which explains the disease phenotype
based on the molecular alterations of enzyme function.
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